Electrophysiological Evidence of Serotonergic Impairment in Long-Term MDMA (“Ecstasy”) Users
- 1 October 2001
- journal article
- research article
- Published by American Psychiatric Association Publishing in American Journal of Psychiatry
- Vol. 158 (10) , 1687-1692
- https://doi.org/10.1176/appi.ajp.158.10.1687
Abstract
OBJECTIVE: “Ecstasy,” or 3,4-methylenedioxymethamphetamine (MDMA), causes long-term impairment to the serotonin (5-HT) system in rats, dogs, and nonhuman primates. 5-HT dysfunction has also been observed in human recreational users of the drug, but whether 5-HT dysfunction in humans is caused by MDMA has not been established, since dysfunction may have preceded MDMA exposure. This ambiguity about causation is particularly important in MDMA research, because 5-HT deficiency is a predictor of risky behavior. METHOD: The 5-HT function of 22 long-term MDMA users was compared to that of 20 drug-naive comparison subjects and 19 cannabis users. 5-HT function was assessed with the intensity dependence paradigm, a tool that measures 5-HT-related attenuation of neural response to auditory stimuli (measured with EEG). RESULTS: Long-term MDMA users exhibited 5-HT dysfunction, relative to both cannabis users and drug-naive comparison subjects. This dysfunction was related to total MDMA consumption (after removing the effect of frequency of use) but not to frequency of use (after removing the effect of total consumption). CONCLUSIONS: These data show that 5-HT dysfunction occurs in MDMA users, is related to users’ MDMA consumption, and is independent of cannabis use. The results do not suggest that self-medication explains this relationship, because the deficit was related to total MDMA consumption but not frequency of consumption. The results are thus consistent with the thesis that MDMA consumption causes 5-HT impairment in humans.Keywords
This publication has 33 references indexed in Scilit:
- The relative contributions of ecstasy and cannabis to cognitive impairmentPsychopharmacology, 2000
- Intensity dependence of auditory evoked potentials (AEPs) as biological marker for cerebral serotonin levels: effects of tryptophan depletion in healthy subjectsPsychopharmacology, 1999
- Opposite effects of 3,4-methylenedioxymethamphetamine (MDMA) on sensorimotor gating in rats versus healthy humans.Psychopharmacology, 1999
- Cognitive performance in (±) 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") users: a controlled studyPsychopharmacology, 1999
- Memory deficits associated with recreational use of "ecstasy" (MDMA)Psychopharmacology, 1999
- In vivo detection of short- and long-term MDMA neurotoxicity?a positron emission tomography study in the living baboon brainSynapse, 1998
- Causes and consequences of the loss of serotonergic presynapses elicited by the consumption of 3,4-methylenedioxymethamphetamine (MDMA, ?ecstasy?) and its congenersJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1997
- Do patients use marijuana as an antidepressant?Depression, 1996
- Neuroendocrine and Mood Responses to Intravenous L-Tryptophan in 3,4-Methylenedioxymethamphetamine (MDMA) UsersArchives of General Psychiatry, 1989
- (+/-)3,4-Methylenedioxymethamphetamine selectively damages central serotonergic neurons in nonhuman primatesJAMA, 1988